l*o
2 楼
约见女网友早已不是什么新鲜事了，但这其中却充满了各种套路和陷阱。近日，安徽一
名男子报警称，自己在火车站准备回江苏老家，却被一女子百般阻挠不让走。这到底是
怎么一回事呢？
蒋先生来自江苏，他通过网络认识了安徽的何女士，两人相谈甚欢，于是自以为人生即
将迎来第二春的他不远千里来到安徽与何女士相见。
见面第一天，何女士就带着蒋先生见了一名经理。据蒋先生称：“那名经理给我上课，
想给我洗脑，但是我曾经被骗过2万块，又怎么会再上当呢？”。
于是第二天，蒋先生与何女士告别：“你们这是传销，我要回家了”。结果被何女士一
路纠缠到火车站就是不让他走。更有意思的是，何女士要求蒋先生带她回家。
而何女士的理由竟是：你没有老婆为什么不敢带我回家？这可把蒋先生问乐了说道：“
大姐，我只是想和你谈个恋爱而已，这跟我有没有老婆有啥关系？”一番争论后见无果
，最终蒋先生选择了报警。
民警到达现场后将二人带回所里进一步了解情况，在得知何女士可能涉嫌传销事件后带
其去了她的住所进行搜查，这一去可真民警们大吃一惊！
这位女子为了发展传销成员可谓是煞费苦心。在这些信纸中记录的都是她物色好的男人
信息，包括其爱好特长等个人信息。随后民警就将这些资料带回所里进行审问。
何女士在证据面前竟调侃起民警：“这些东西我也没有必要讲，因为讲了你也听不懂，
如果你懂了，也会做这行的！”
此话一出，小编好奇这何女士的脑子到底被洗了多少次？言归正传，后来何女士被警方
采取强制措施，目前还在进一步审理中。
对此有网友表示疑问：为什么是第二天才走，两人到底发生关系没有？小编只想说，
这位网友兄弟，你能正经点不？！欢迎广大网友留言评论...
名男子报警称，自己在火车站准备回江苏老家，却被一女子百般阻挠不让走。这到底是
怎么一回事呢？
蒋先生来自江苏，他通过网络认识了安徽的何女士，两人相谈甚欢，于是自以为人生即
将迎来第二春的他不远千里来到安徽与何女士相见。
见面第一天，何女士就带着蒋先生见了一名经理。据蒋先生称：“那名经理给我上课，
想给我洗脑，但是我曾经被骗过2万块，又怎么会再上当呢？”。
于是第二天，蒋先生与何女士告别：“你们这是传销，我要回家了”。结果被何女士一
路纠缠到火车站就是不让他走。更有意思的是，何女士要求蒋先生带她回家。
而何女士的理由竟是：你没有老婆为什么不敢带我回家？这可把蒋先生问乐了说道：“
大姐，我只是想和你谈个恋爱而已，这跟我有没有老婆有啥关系？”一番争论后见无果
，最终蒋先生选择了报警。
民警到达现场后将二人带回所里进一步了解情况，在得知何女士可能涉嫌传销事件后带
其去了她的住所进行搜查，这一去可真民警们大吃一惊！
这位女子为了发展传销成员可谓是煞费苦心。在这些信纸中记录的都是她物色好的男人
信息，包括其爱好特长等个人信息。随后民警就将这些资料带回所里进行审问。
何女士在证据面前竟调侃起民警：“这些东西我也没有必要讲，因为讲了你也听不懂，
如果你懂了，也会做这行的！”
此话一出，小编好奇这何女士的脑子到底被洗了多少次？言归正传，后来何女士被警方
采取强制措施，目前还在进一步审理中。
对此有网友表示疑问：为什么是第二天才走，两人到底发生关系没有？小编只想说，
这位网友兄弟，你能正经点不？！欢迎广大网友留言评论...
s*a
3 楼
http://www.philly.com/philly/health/HealthDay668074_20120827_FD
MONDAY, Aug. 27 (HealthDay News) -- A new pill to treat HIV infection that
combines four medicines and only has to be taken once a day was approved by
the U.S. Food and Drug Administration on Monday.
Stribild, which will be marketed by maker Gilead Sciences, contains the HIV
drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
fumarate. It will be prescribed to people who have never been treated for
HIV infection, the agency said in a statement.
Two of the drugs, elvitegravir and cobicistat, are new, the FDA noted.
Elvitegravir interferes with one of the enzymes that HIV needs to multiply,
while cobicistat inhibits an enzyme that metabolizes certain HIV drugs and
so prolongs the effect of elvitegravir. The combination of emtricitabine and
tenofovir disoproxil fumarate is already marketed as Truvada, and they work
in concert to block another enzyme that HIV needs to replicate.
"Through continued research and drug development, treatment for those
infected with HIV has evolved from multi-pill regimens to single-pill
regimens," Dr. Edward Cox, director of the Office of Antimicrobial Products
in FDA's Center for Drug Evaluation and Research, said in the agency
statement. "New combination HIV drugs like Stribild help simplify treatment
regimens."
Earlier this year, the agency approved the first over-the-counter rapid HIV
test for home use and gave its blessing to the first drug to be used to
prevent HIV infection when used together with safe sex practices.
Two clinical trials found between 88 percent and 90 percent of patients
treated with Stribild had an undetectable amount of HIV in their blood after
48 weeks of treatment, the FDA said.
The drug will carry a boxed warning that says it can cause a build-up of
lactic acid in the blood and severe liver problems, both of which can be
fatal. In the clinical trials, common side effects included nausea and
diarrhea. Serious side effects include new or worsening kidney problems,
decreased bone mineral density, fat redistribution and changes in the immune
system, the FDA said.
Gilead, which is based in Foster City, Calif., must conduct more research to
further determine the drug's safety in women and children, how resistance
develops to Stribild and possible interactions with other drugs, the FDA
said.
MONDAY, Aug. 27 (HealthDay News) -- A new pill to treat HIV infection that
combines four medicines and only has to be taken once a day was approved by
the U.S. Food and Drug Administration on Monday.
Stribild, which will be marketed by maker Gilead Sciences, contains the HIV
drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
fumarate. It will be prescribed to people who have never been treated for
HIV infection, the agency said in a statement.
Two of the drugs, elvitegravir and cobicistat, are new, the FDA noted.
Elvitegravir interferes with one of the enzymes that HIV needs to multiply,
while cobicistat inhibits an enzyme that metabolizes certain HIV drugs and
so prolongs the effect of elvitegravir. The combination of emtricitabine and
tenofovir disoproxil fumarate is already marketed as Truvada, and they work
in concert to block another enzyme that HIV needs to replicate.
"Through continued research and drug development, treatment for those
infected with HIV has evolved from multi-pill regimens to single-pill
regimens," Dr. Edward Cox, director of the Office of Antimicrobial Products
in FDA's Center for Drug Evaluation and Research, said in the agency
statement. "New combination HIV drugs like Stribild help simplify treatment
regimens."
Earlier this year, the agency approved the first over-the-counter rapid HIV
test for home use and gave its blessing to the first drug to be used to
prevent HIV infection when used together with safe sex practices.
Two clinical trials found between 88 percent and 90 percent of patients
treated with Stribild had an undetectable amount of HIV in their blood after
48 weeks of treatment, the FDA said.
The drug will carry a boxed warning that says it can cause a build-up of
lactic acid in the blood and severe liver problems, both of which can be
fatal. In the clinical trials, common side effects included nausea and
diarrhea. Serious side effects include new or worsening kidney problems,
decreased bone mineral density, fat redistribution and changes in the immune
system, the FDA said.
Gilead, which is based in Foster City, Calif., must conduct more research to
further determine the drug's safety in women and children, how resistance
develops to Stribild and possible interactions with other drugs, the FDA
said.
t*6
4 楼
not really.
d*m
5 楼
这女的看图是个美女
j*e
6 楼
why?
相关阅读
清大施一公，华大王俊，谁先的诺奖？11g回国后得到的资源我们身体上那些难以言明的奇怪的症状，99%的人都出现过zz免疫学基本问题:到底CD28在CD8+ T cell activation是否起作用SYG这个诺奖又能骗不少无知的高中生学生物了吧生物科研变成民工搬砖谁功劳最大？2 Guest editor needed (microbial genomics, bacterial genetics, Metagenomics, 16S DNA, water system)那个领域想成功不是需要努力的？国内为什么会炒出一万块一瓶的普通细胞培养血清？学生物的，在湾区，能混下去吗？免疫荧光可以用来测定蛋白表达丰度吗？速冻就真的不会影响结构吗？test有偿急求3-5篇免疫和干细胞领域的审稿机会。MD anderson和MSKCC那个basic research更牛？十一公诺奖？诺奖这么跌分了？不要再讨论11公了，好无聊一公是诺奖候选人羞于媒体和争议的异类求审稿机会：microbiology, antibiotics, infectious diseases 长期有效！！！！Paper help please.